Adjuvant Chemotherapy in Osteosarcoma

摘要: Osteosarcoma is the most common malignant bone tumor affecting children and adolescents. The biological behavior consistent with premise that pulmonary micrometastases are present at diagnosis in majority of patients. These silent undetected on imaging studies. They usually surface six to twelve months following amputation primary if untreated responsible for patients demise. Until 1970s was generally considered be chemoresistant. However, early 1970’s, two chemotherapeutic agents were found active osteosarcoma. comprised Adriamycin (doxorubicin) high-dose Methotrexate Citrovorin factor rescue (Leucovorin rescue). administration alone or combination other yielded a cure rate 40-65 percent. This attributed destruction micrometastases. improved survival due chemotherapy did not go unchallenged. Mayo Clinic adduced data suggest there had been “natural improvement” over several years it should necessarily assumed chemotherapy, particularly Methotrexate, improvement. veracity historical controls efficacy high dose also disputed by additional claims from Clinic. Principal among these recent advances diagnostic techniques i.e. CT lung radionuclide scans.